If JUNO's Liso-Cel is approved it will be 12 months from now. I don't think it comes close to matching up with ZUMA 1 (or other ZUMA trials with CR as high as 80%), and FDA surely knows the same, so I say Liso-Cel isn't worthy of approval - especially since the CR is lower than ZUMA 1 (over 250 patients including real life).
Why would a doctor / hospital ask for it over Yescarta? CR rate of 46% is NOT better than Yescarta in real world.
JUNO missed the boat IMO.
Kymriah's manufacturing issues got so bad that FDA would not let them sell it commercially - but could only give it away.
GILD on the other hand has had zero manufacturing issues with their CAR T.
Yescarta will have 4 years of no deaths by the time Liso-Cel (just old JCAR15?) https://www.fiercebiotech.com/r-d/juno-ditches-lead-car-t-program-following-patient-deaths